Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NS 2359

Drug Profile

NS 2359

Alternative Names: 372475; GSK 372475

Latest Information Update: 24 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroSearch
  • Developer National Institute on Drug Abuse; Saniona; University of Pennsylvania
  • Class Antidepressants; Drug withdrawal therapies; Nootropics; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cocaine abuse
  • Discontinued Alcoholism; Attention-deficit hyperactivity disorder; Major depressive disorder

Most Recent Events

  • 23 Jan 2019 The University of Pennsylvania Treatment Research Center (TRC) plans to continue the ongoing phase II study for NS 2359 in cocaine addiction at a higher dose
  • 24 Jun 2018 Biomarkers information updated
  • 14 Sep 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top